NeuroNEXT Network

Standard Operating Procedure (SOP)
Study Materials Development
Version 2.0
SOP NN PM 503

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

Christopher St. Coffey, PhD (DCC Principal Investigator)

Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)

Marianne Kearney Chase, BA (CCC Director of Clinical Operations)

Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Katherine B. Gloer, PhD (DCC Quality Management Lead)

Janice Cordell, RN MPH (NIH, NeuroNEXT Program Official)

September 21, 2016
Issue Date

October 21, 2016
Effective Date (30 calendar days after the Issue Date)
1. POLICY

For all studies approved to be conducted within the NeuroNEXT Network, the Clinical Coordinating Center (CCC) will work with the Data Coordinating Center (DCC) and the Protocol Principal Investigator (PPI) or his/her designee to develop study-specific templates and other materials to be used by Clinical Study Sites (CSS) in the conduct of study-related activities. The CCC and DCC will collaborate to develop additional Network templates and materials that are used across NeuroNEXT studies, as needed. Study materials are posted to the internal study website and are accessible to all authorized NeuroNEXT personnel.

The following sections present examples of study materials that are typically developed for each NeuroNEXT study.

**Manual of Operations (i.e. Manual of Procedures; MOP)**

A MOP is a study-specific, version-controlled document that describes study processes and procedures. A MOP is developed for every NeuroNEXT study, and is used as a reference and a training tool for instructing CSS personnel on study conduct.

The study MOP incorporates an organizational plan that defines responsibilities, a study roster that contains contact information for the Study Team, and a communications plan that provides contact information for specific members of the Study Team who are directly involved with study management.

The MOP also includes a training plan, information on study logistics and procedures, a plan for recruitment and retention, and study enrollment procedures. Instructions related to protocol compliance, study medications, concomitant and prohibited medications, safety reporting, outcome measures, data collection and management, study closeout, and confidentiality and publication are also typically included in the study MOP. The MOP also may also describe laboratory procedures, including directions for processing and shipping laboratory specimens and directions for ordering/re-ordering study supplies and investigational product, as applicable.

The PPI, appropriate CCC and DCC personnel, and a representative from the Sponsor Company (if applicable) sign off on the study MOP and any subsequent revisions or amendments.

**Other Study-Specific Materials**

The following study-specific materials may be developed for use in a study (as applicable):

- Data collection templates and related materials
  - Source documents
  - Data entry templates
  - CRF forms grid
  - Assessment instruments (e.g. questionnaires, quizzes)
- Study-specific guidance documents, training manuals and materials, or user’s manuals, such as:
  - Website and data entry user’s manuals
  - Imaging manual and shipping instructions
  - Educational materials (e.g., videos, slide presentations)
Laboratory manuals
  - Specimen processing and tracking manual
  - Temperature logs for freezers

Pharmacy manuals
  - Site pharmacy manual
  - Study medication administration instructions
  - Study drug dispensing system user’s manual
  - Study drug accountability log

Network Templates and Materials
- Standard Operating Procedures (SOPs)
- Study staff Delegation of Responsibilities (DOR) log template
- Addition of study staff form
- Study staff certification form
- Note to File template
- Data Change Request (DCR) form template

2. SCOPE
This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 1996 ICH E6 Consolidated Guidance. The policies and procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES
The CCC, DCC, and PPI or his/her designee are responsible for developing a study-specific materials such as a MOP, source documents, and other materials and tools that may assist CSS in the conduct of the study.

The CCC and DCC are responsible for developing Network-wide templates and materials, when needed.

4. APPLICABLE REGULATIONS AND GUIDELINES
   21 CFR 312.50        General Responsibilities of Sponsors
   ICH E6               The Principles of ICH GCP

5. REFERENCES TO OTHER APPLICABLE SOPS
   NN GA 103            Document Development and Change Control

6. ATTACHMENTS AND REFERENCES
   NN PM 502 – A        Document History

7. TERMS AND ABBREVIATIONS
   The following terms and abbreviations are used in this document:
   
   CCC  Clinical Coordinating Center at Massachusetts General Hospital
   CSS  Clinical Study Site
### 8. SPECIFIC PROCEDURES

#### A. Manual of Operations (MOP)

<table>
<thead>
<tr>
<th>#</th>
<th>Who</th>
<th>Task</th>
<th>Attachment / References</th>
<th>Related SOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>CCC, DCC, and PPI or designee</td>
<td>Draft a Manual of Operations (MOP) that describes study processes, procedures, and responsibilities of the CCC, DCC, study management personnel, and other key study personnel (if applicable).</td>
<td>NN GA 103</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>PPI and applicable CCC and DCC personnel; Sponsor Company representative (if applicable)</td>
<td>Sign off on the final version of the MOP.</td>
<td>NN GA 103</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>CCC, DCC</td>
<td>Provide each participating CSS access to the MOP on the internal study website.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>PPI and applicable CCC and DCC personnel; Sponsor Company representative (if applicable)</td>
<td>Revise the MOP as necessary, and re-sign the revised version.</td>
<td>NN GA 103</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>CCC, DCC</td>
<td>Provide each participating CSS access to the updated/amended MOP.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### B. Other Study Materials

<table>
<thead>
<tr>
<th>#</th>
<th>Who</th>
<th>Task</th>
<th>Attachment / References</th>
<th>Related SOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>CCC, DCC, and PPI or designee</td>
<td>Develop study-specific materials and tools as deemed appropriate for each study.</td>
<td>NN GA 103</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>CCC, DCC</td>
<td>Provide each participating CSS access to study materials and tools on the internal study website.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>CCC, DCC, and PPI or designee</td>
<td>Revise study materials and tools, as needed.</td>
<td>NN GA 103</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>CCC, DCC</td>
<td>Provide each participating CSS access to updated study materials and tools on the internal study website, as needed.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## NeuroNEXT Network Standard Operating Procedure (SOP)
### Study Materials Development

**SOP NN PM 503**

<table>
<thead>
<tr>
<th>Version</th>
<th>Description of Modification</th>
<th>Reason or Justification for Modification</th>
<th>Issue Date</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>New</td>
<td>N/A</td>
<td>06Apr2012</td>
<td>06May2012</td>
</tr>
<tr>
<td>2.0</td>
<td>Extensively revised to include a description of the study Manual of Operations (i.e. Manual of Procedures; MOP), and listings of other study-specific and Network materials that may be developed to assist CSS with proper study conduct. Removed references to a study manual for CSS.</td>
<td>Updates for version 2.0</td>
<td>21Sep2016</td>
<td>21Oct2016</td>
</tr>
</tbody>
</table>